#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Psychiatry in everyday life


Authors: prof. MUDr. CSc. Eva Češková
Authors‘ workplace: CEITEC-MU, Psychiatrická klinika LF MU a FN Brno, Oddělení psychiatrické FN Ostrava, katedra interních oborů LF OU
Published in: Čas. Lék. čes. 2016; 155: 206-208
Category: Review Article

Overview

Severe mental disorders including its main representative schizophrenia are chronic lifelong diseases. Most patients like those with somatic disease can live in the society under certain conditions as continuous psychopharmacotherapy and availability of community services. Similarly as in somatic medicine a great attentions is devoted to the individualized treatment.

Psychotic disorders have some specific features, like lack of insight associated with poor adherence. Nowadays we have a possibility of an objective adherence evaluation by plasma levels measurement and the depots, long-action injections of antipsychotics (including the second generation antipsychotics), are available. Unfortunately this modern approach is restricted by insurance companies.

In spite of the fact that therapeutic drug monitoring is an advantageous tool for treatment optimization this interdisciplinary service is in many faculty and regional hospitals not provided. Providers of health care should realise that accessibility of some services and medication could reduce the danger of untreated psychosis.

Keywords:
psychosis, psychopharmacotherapy, adherence, depots, therapeutic drug monitoring.


Sources

1. Raboch J, Wenigová B. Mapování stavu psychiatrické péče a jejího směřování v souladu se strategickými dokumenty České republiky (a zahraničí). Odborná zpráva z projektu. Česká psychiatrická společnost, o. s., Praha, 2012.

2. Zohar J, Nutt D, Kupfer J et al. A proposal for an updated neuropsychopharmacological nomenclature. Eur Neuropsychopharmacol 2014; 24: 1005−1014.

3. Wegener G, Rujescu D. The current development of CNS drug research. Int J Neuropsychopharmacol 2013; 16: 1687−1693.

4. Witchen HU, Jacobi F, Rehm J et al. The size and burden of mental disorders and other disorders of the brain in Europe. Eur Neuropsychopharmacol 2011; 21: 655−679.

5. Hasan A, Falkai P, Wobrock T et al. WFSBP Task force on Treatment Guidelines for Schizophrenia. Word Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological treatment of Schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects. World J Biol Psychiatry 2013; 14: 2−44.

6. Češková E, Přikryl R, Péč O. Schizofrenie dospělého věku. V: Psychiatrie. Doporučené postupy psychiatrické péče IV (eds.: Uhlíková P, Hellerova P, Anders M, Šusta M.). Česká psychiatrická společnost, 2014: 112−117.

7. Masopust J, Malý R, Tůma I. Kardiovaskulární rizika léčby antipsychotiky. Remedia 2006; 16: 587−593.

8. Keshavan MS, Vinogradov S, Rumsey J et al. Cognitive training in mental disorders: update and future directions. Am J Psychiatry 2014; 171: 510−522.

9. Češková E, Vrzalová M. Optimalizace farmakoterapie schizofrenní poruchy. Psychiatrie pro praxi 2012; 13: 156−159.

10. Hamann J, Mendel R, Cohen R et al. Psychiatrists' use of shared decision making in the treatment of schizophrenia: patient characteristics and decision topics. Psychiatr Serv 2009; 60: 1107−1112.

11. Hiemke C, Shams M. Phenotyping and genotyping of drug metabolism to guide pharmacotherapy in psychiatry. Curr Drug Deliv 2013; 10: 46-53.

Labels
Addictology Allergology and clinical immunology Angiology Audiology Clinical biochemistry Dermatology & STDs Paediatric gastroenterology Paediatric surgery Paediatric cardiology Paediatric neurology Paediatric ENT Paediatric psychiatry Paediatric rheumatology Diabetology Pharmacy Vascular surgery Pain management
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#